AstraZeneca seeks EU approval for COVID vaccine

The Oxford-AstraZeneca jab is cheaper to produce than its rivals, and easier to store and transport than the Pfizer-BioNTech vaccine in particular, which requires ultra-low freezing temperature.;

Published On 2021-01-13 08:30 GMT | Update On 2021-01-13 08:30 GMT

New Delhi: AstraZeneca and Oxford University have applied for authorisation for their coronavirus vaccine in the EU with a decision possible by January 29, the European Medicines Agency said on Tuesday.

The jab would be the third available for the 27-nation European Union after the Pfizer-BioNTech and Moderna drugs, as the bloc struggles to speed up the rollout.

"EMA has received an application for conditional marketing authorisation for a COVID-19 vaccine developed by AstraZeneca and Oxford University," the Amsterdam-based regulator said in a statement.

The EMA said its assessment would "proceed under an accelerated timeline".

"An opinion on the marketing authorisation could be issued by 29 January... provided that the data submitted on the quality, safety and efficacy of the vaccine are sufficiently robust and complete," it said.

The EU and the EMA have been under pressure to speed up approval of new vaccines against the virus, which has claimed the lives of more than 620,000 people across the continent.

European Commission chief Ursula von der Leyen hailed the application by Oxford-AstraZeneca as "good news".

"Once the vaccine receives a positive scientific opinion, we will work full speed to authorise its use in Europe," she said on Twitter.

The Oxford-AstraZeneca jab is cheaper to produce than its rivals, and easier to store and transport than the Pfizer-BioNTech vaccine in particular, which requires ultra-low freezing temperature.

It is based on a weakened version of a common cold virus (adenovirus) in chimpanzees which has been genetically changed to stop Covid-19 replicating in humans.

Oxford-AstraZeneca has previously been criticised over a lack of clarity and transparency on trials that had shown varying outcomes in the jab's efficiency.

Initial large-scale trials in which volunteers in the UK and Brazil were given two full doses showed 62 percent effectiveness.

For volunteers who received a half-dose first and then a full dose one month later, however, the vaccine was found to have 90 percent efficacy.

The EMA said it had already been reviewing data from "four ongoing clinical trials" in Britain, Brazil and South Africa.

"Additional scientific information on issues related to quality, safety and efficacy of the vaccine was also provided by the company at the request of (the EMA) and is currently being assessed," it added.

Article Source : AFP

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

AstraZeneca seeks EU approval for COVID vaccine

The Oxford-AstraZeneca jab is cheaper to produce than its rivals, and easier to store and transport than the Pfizer-BioNTech vaccine in particular, which requires ultra-low freezing temperature.;

Similar News

Sanofi Tolebrutinib faces USFDA review delay; new target action date set for December 28

CDSCO Panel Flags Trial Death, Seeks Causality Report from Reliance Life Sciences on EtanerRel

Spurious Drugs Alert: Diazepam, PAN 40, and PAN-D Capsules Under Investigation

CDSCO Panel Approves Cipla's Levormeloxifene Study Amendment, Mandates Transvaginal Sonography

115 hospital pharmacies in Telangana receive show cause notices

AstraZeneca-Amgen Tezspire recommended for approval in EU for chronic rhinosinusitis with nasal polyps

CII, ICON host strategic dialogue on Indian pharma move toward US manufacturing

Medicines worth Rs 50000 seized from quack clinic in Telangana